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Objective: Mucinous breast carcinoma (MBC) is classified into mixed mucinous breast carcinoma (MMBC) and pure
mucinous breast carcinoma (PMBC) based on whether the tumor is with or without a component of invasive ductal
carcinoma, respectively. PMBC is subtyped into hypocellular PMBC (PMBC-A) and hypercellular PMBC (PMBC-B).
Methods: Of 1,760 primary breast carcinomas, 71 were diagnosed as MBC, and were subtyped for comparison
purposes.
Results: Seventy-one of all breast cancers (4.0%) were MBC, and consisted of 23 MMBC, 32 PMBC-A and 16 PMBC-B.
The MBC tumors were more often hormone receptor-positive and HER2-negative than non-MBC tumors. Patients
with MMBC, PMBC-B or PMBC-A, in this order, had significantly higher recurrence rates than non-MBC cases
(p=0.006, log-rank).
Conclusions: In the NCCN guidelines, MBC is also regarded as “a histological type with a favorable prognosis”
in a uniform manner, and “treatment for a histological type with a favorable prognosis” is recommended.
However, the results of this study suggest that sub-classification-based, individualized therapeutic strategies
should be considered.
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Mucinous breast carcinoma (MBC), a special type of
breast carcinoma, is the second most common cancer
after lobular carcinoma, accounting for 1.3 - 5.4% of all
breast cancers (Ellis et al. 2003; Fentiman et al. 1977;
Komaki et al. 1988; Scopsi et al. 1994; Anan et al. 2001).
According to the current General Rules for Clinical and
Pathological Recording of Breast Cancer, MBC is charac-
terized by the fact that the cancer cells produce mucus,
and nests of mucinous cancer cells occupy almost the
entire tumor mass (Wilson et al. 1955). In the WHO
classification of breast tumors, MBC is described as a
subtype of mucinous carcinoma and other tumors with
abundant mucus (mucin-producing carcinomas) (Ellis et al.
2003). It is histologically subtyped into mixed mucinous
breast carcinoma (MMBC) containing a component of* Correspondence: spqv9ke9@view.ocn.ne.jp
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ous breast carcinoma (PMBC), in which nests of mucin-
ous cancer cells occupy almost the entire tumor mass, and
which contains no component of conventional invasive
ductal carcinoma (Capella et al. 1980; Ranade et al. 2010;
Rosen 2008; André et al. 1995). PMBC may be subtyped
into a hypocellular variant (PMBC-A) showing a tubular,
cribriform, cord-like, micropapillary or papillary growth
pattern, and a hypercellular variant (PMBC-B) growing in
solid nests (Capella et al. 1980; Ranade et al. 2010). In this
study, we clinicopathologically analyzed MBC according
to these subtypes.Materials and methods
Patient background
A total of 1,760 patients with primary breast cancer
underwent surgery between January 2000 and December
2012. Of these patients, 71 (4.0%) were diagnosed with
MBC. These MBC cases were subtyped into MMBC,
PMBC-A and PMBC-B for comparison purposes. Theis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Demographical data of 71 patients with
mucinous carcinoma of the breast
Parameters (n=71) Percentage
Age mean 61.8 (26 – 95, median 64)
Tumor diameter (cm) mean 3.1 (0.5 – 12.3, median 2.5)
Tumor location 39 (54.9%)/32 (45.1%)
right/left
Subtype 23 (32.4%)/32 (45.1%)/
16 (22.5%)
MMBC/PMBC-A / PMBC-B
Pathological stage 23 (32.4%)/40 (56.3%)/
8 (11.3%)
I/II/III
pT 23 (32.4%)/38 (53.5%)/
6 (8.5%)/ 4 (5.6%)
T1/T2/T3/T4
pLymph node status 8 (11.3%)/63 (88.7%)
Positive/Negative
Lymphovascular invasion 15 (21.1%)/56 (78.9%)
Positive/Negative
Nuclear grade 55 (77.5%)/15 (21.1%)/
1 (1.4%)
1/2/3
EIC 31 (43.7%)/40 (56.3%)
Positive/Negative
Hormone receptor status 68 (95.8%)/3 (4.2%)
Positive/Negative
HER 2 status 1 (1.4%)/70 (98.6%)
Positive/Negative
Ki67 8 (11.3%)/63 (88.7%)
Positive/Negative
Recurrence 7 (9.9%)/64 (90.1%)
Recurrence/no- Recurrence
Recurrence cases (n=7) 6 (85.7%)/0 (0.0%)/1 (14.3%)
MMBC/PMBC-A/PMBC-B
MMBC mixed mucinous carcinoma, PMBC pure mucinous carcinoma, EIC
extensive intraductal component.
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10.1 years).
Immunohistochemistry
The hormone receptor (HR), human epidermal growth
factor receptor 2 (HER2) expression and proliferative
activity, as measured by the Ki67 labeling index, were
evaluated by immunohistochemical staining of formalin-
fixed, paraffin-embedded surgical breast cancer speci-
mens using the ABC method. For antigen activation,
deparaffinized sections were immersed in 0.01 M citrate
buffer (pH 6.0), and heated at 105°C for 10 min. Primary
antibodies against the ER (clone 1D5, dilution 1:80;
Dako, Carpinteria, California, USA), PR (clone PgR636,
dilution 1:100; Dako), HER2 (Hercep Test™, Dako) and
Ki67 (clone MIB-1, dilution 1:100; Dako) were used. En-
dogenous peroxidase activity was blocked with 0.3%
H2O2 in methanol, color was developed with DAB (3, 3-
diaminobenzidine, tetrahydrochloride) and the sections
were counterstained with Meyer’s hematoxylin. A patho-
logical diagnosis was made by two pathologists who spe-
cialized in mammary gland pathology using the blind
method to confirm the objectivity and reproducibility of
the diagnosis.
Immunohistochemical scoring
For the hormone receptors, any staining was considered
to indicate a positive sample. HER2 reactivity was assessed
according to the ASCO/CAP guidelines. The Ki67 labeling
index was evaluated as a percentage of positive cells
among more than 1,000 cancer cells in five high-powered
fields (HPFs) of the deepest portion and margin of the
superficial layer of the tumor, and a percentage of 14% or
higher was considered to be positive.
Statistical analysis
Statistical analysis was performed using SPSS version
13.0 statistical software (IBM, Armonk, New York,
USA). Clinicopathological factors were analyzed in MBC
patients using the chi-square test. Disease-free survival
rates were calculated using the Kaplan-Meier method,
and significance was assessed using the log-rank test. A
value of p < 0.05 was considered to be significant.
Results
Of the 1,760 patients who underwent surgery for pri-
mary breast cancer, 71 (4.0%), 23 (32.4%), 32 (45.1%) and
16 (22.5%) had MBC, MMB, PMBC-A and PMBC-B,
respectively. Table 1 shows their clinicopathological
characteristics. Their mean age was 61.8 years (range,
26–95 years; median, 64 years). The mean tumor diameter
was 3.1 cm (range, 0.5–12.3 cm; median, 2.5 cm). Eight
(11.3%), fifteen (21.1%), and 31 patients (43.7%) had lymph
node metastasis, vascular invasion and an extensiveintraductal component (EIC), respectively. Breast cancer
subtyping based on the hormone receptor (HR) and
HER2 expression showed that, of the 71 tumors, 68
(95.8%), one (1.4%) and two (2.8%) were HR-positive/
HER2-negative, HR-negative/HER2-postive and HR-
negative/HER2-negative (so-called triple-negative), re-
spectively. Of the seven patients with recurrence, six
(85.7%) had MMBC, none had PMBC-A, one (14.3%)
had PMBC-B, and none of the patients had died.
The clinicopathological analysis revealed that MBCs had
a significantly larger diameter than non-MBCs (p=0.001),
and were significantly more frequently HR-positive (p<0.001)
Figure 1 Correlation between the mucinous carcinoma phenotype an
mucinous breast carcinoma patients experienced significantly poorer outcomes
Table 2 Clinicopathologic feature of 71 mucinous breast
cancers in 1760 breast carcinomas
Parameters MBC (n=71) Non-MBC (n=1689) p value
Age at operation 38 (53.5%) 965 (57.1%) 0.547
≤64 33 (46.5%) 724 (42.9%)
>64
Pathological stage 23 (32.4%) 799 (47.3%) 0.014
I 48 (67.6%) 890 (52.7%)
II and III
pTumor size 25 (35.2%) 937 (55.5%) 0.001
≤2 cm 46 (64.8%) 752 (45.5%)
>2 cm
pLymph node status 63 (88.7%) 1270 (75.2%) 0.009
Negative 8 (11.3%) 419 (24.8%)
Positive
Lymphovascular invasion 56 (78.9%) 1276 (75.5%) 0.522
Negative 15 (21.1%) 413 (24.5%)
Positive
HR (ER and/or PR) 3 (4.2%) 477 (28.2%) < 0.001
Negative 68 (95.8%) 1212 (71.8%)
Positive
HER 2 status 70 (98.6%) 1310 (77.6%) < 0.001
Negative 1 (1.4%) 379 (22.4%)
Positive
MBC mucinous breast carcinoma.
HR Hormone receptor.
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(Table 2).
Among all patients (n=1,760), there was no significant
difference in the DFS between those with MBC and
those with non-MBC tumors (p=0.614, log-rank test)
(Figure 1a). However, a subtype analysis showed that pa-
tients with MMBC, PMBC-B or PMBC-A, in this order,
had a significantly higher recurrence rate than those with
non-MBC tumors (p=0.006, log-rank test) (Figure 1b).
Among the 71 MBCs, MMBC showed a significantly
higher Ki67 labeling index (P=0.010) and nuclear grade
(p <0.001) than PMBC, and these were not correlated with
the HR or HER2 expression (Table 3). Among the 48
PMBCs, no significant differences in the clinicopathologi-
cal characteristics were noted between patients with
PBMC-A and those with PMBC-B.
The patients with recurrence were divided into those
with and without lymph node metastasis, and their pri-
mary tumors and metastatic lymph nodes were patho-
logically examined. As a result, other pathological types
coexisting with MBC (Figure 2a) were also confirmed to
be present in the metastatic lymph nodes (Figure 2b). A
mucus-rich lesion, as seen in the primary tumor (Figure 2c),
was also observed in the metastatic lymph nodes (Figure 2d)
of the patients with PMBC-A who had no recurrence in
the presence of lymph node metastasis.
Discussion
It has been reported that MBC shows a favorable prog-
nosis, with a 10-year survival rate of more than 90%
(Fentiman et al. 1977; Komaki et al. 1988; Di Saverio et al.
2008). Since a higher ratio of the extracellular mucusd disease-free survival in the breast cancer series. The mixed
in all breast cancers (a) and mucinous carcinomas (b). (NS; not significant).
Table 3 Correlations between subtype and clinicopathological parameters in 71 mucinous breast carcinomas
Parameters MBC (n=71) p value PMBC (n=48) p value
MMBC (n=23) PMBC (n=48) PMBC-A (n=32) PMBC-B (n=16)
Age at operation 14 (60.9%) 24 (50.0%) 0.390 14 (43.8%) 10 (62.5%) 0.220
≤64 9 (39.1%) 24 (50.0%) 18 (56.2%) 6 (37.5%)
>64
Pathological stage 9 (39.1%) 14 (29.2%) 0.401 8 (25.0%) 6 (37.5%) 0.369
I 14 (60.9%) 34 (70.8%) 24 (75.0%) 10 (62.5%)
II and III
pTumor size 11 (47.8%) 14 (29.2%) 0.123 8 (25.0%) 6 (37.5%) 0.175
≤2 cm 12 (52.2%) 34 (70.8%) 24 (75.0%) 10 (62.5%)
>2 cm
pLymph node status 19 (82.6%) 44 (91.7%) 0.162 30 (93.8%) 14 (87.5%) 0.460
Negative 4 (17.4%) 4 (8.3%) 2 (6.2%) 2 (12.5%)
Positive
Lymphovascular invasion 16 (69.6%) 40 (83.3%) 0.184 29 (90.6%) 11 (68.8%) 0.057
Negative 7 (30.4%) 8 (16.7%) 3 (9.4%) 5 (32.2%)
Positive
HR (ER and / or PR) 1 (4.3%) 2 (4.2%) 0.454 1 (3.1%) 1 (6.3%) 0.453
Negative 22 (95.7%) 46 (95.8%) 31 (96.9%) 15 (93.7%)
Positive
HER2 status 23 (100.0%) 47 (97.9%) 0.676 31 (96.9%) 16 (100.0%) 0.667
Negative 0 (0.0%) 1 (2.1%) 1 (3.1%) 0 (0.0%)
Positive
Ki67 17 (73.9%) 46 (95.8%) 0.010 30 (93.8%) 16 (100.0%) 0.439
Negative 6 (26.1%) 2 (4.2%) 2 (6.2%) 0 (0.0%)
Positive
Nuclear grade 11 (47.8%) 44 (91.7%) < 0.001 30 (93.8%) 14 (87.5%) 0.306
1 12 (52.2%) 4 (8.3%) 2 (6.2%) 2 (22.5%)
2 and 3
EIC 12 (52.2%) 28 (58.3%) 0.624 20 (62.5%) 8 (50.0%) 0.174
Negative 11 (47.8%) 20 (41.7%) 12 (37.5%) 8 (50.0%)
Positive
BMC breast mucinous carcinoma, MMBC mixed mucinous carcinoma, PMBC pure mucinous carcinoma, HR Hormone receptor, EIC extensive intraductal component.
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with a more favorable prognosis, PMBC-A, PMBC-B and
MMBC, in this order, would be expected to show a favor-
able prognosis (Komaki et al. 1988; Ranade et al. 2010;
Clayton 1986). In this study, there was no significant dif-
ference in the DFS between the patients with MBC and
those with non-MBC tumors. However, a subtype analysis
showed that patients with MMBC had a significantly
higher recurrence rate than those with PMBC, suggesting
the usefulness of breast cancer sub-classification.
Of the seven patients with recurrence in the present
study, six (85.7%) had MMBC, none had PMBC-A and
one (14.3%) had PMBC-B. Of the eight patients withlymph node metastasis, four (three with MMBC and one
with PMBC-B) had recurrence. On the other hand, two
patients with PMBC-A had no recurrence in the pres-
ence of lymph node metastasis. This suggests that
PMBC-A with a high proportion of mucus shows a fa-
vorable prognosis even in the presence of lymph node
metastasis.
From the viewpoint of the intrinsic subtype, MBC tu-
mors were frequently HR-positive/HER2-negative, and
often of the so-called luminal A type (Ki67 labeling
index <14%). Many researchers have reported that most
MBCs are luminal A type, and that this is a clinicopa-
thological characteristic of MBC (Komaki et al. 1988;
Figure 2 Histological findings (H.E. stain x 400). (a) primary lesion of mixed mucinous breast carcinoma. (b) metastatic lymph node of mixed
mucinous breast carcinoma. (c) primary lesion of pure mucinous breast carcinoma type A. (d) metastatic lymph node of pure mucinous breast
carcinoma type A.
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Hormone therapy is a common treatment option used
for patients with luminal A-type breast cancer, but
some MBCs are resistant to treatment, suggesting that
MMBC, which are considered to have a relatively poor
prognosis based on the present results, may have differ-
ent biological properties even within the same tumor
type.
Thus, with regard to the therapeutic strategies based
on the sub-classification of mucinous carcinoma of the
mammary gland, “standard treatment” for a coexisting
histological type should be performed in patients with
MMBC, which shows a high recurrence rate (NCCN
Clinical Practice Guidelines in Oncology Breast Cancer
v.2 2012). Among patients with PMBC, “standard treat-
ment” or “treatment for a histological type with a favor-
able prognosis” should be selected based on the presence
or absence of lymph node metastasis in those with
PMBC-B. On the other hand, in those with PMBC-A,
“treatment for a histological type with a favorable progno-
sis” may be selected, regardless of the presence or absence
of lymph node metastasis.
In the NCCN guidelines, MBC is also regarded as “a
histological type with a favorable prognosis” in a uniformmanner, and “treatment for a histological type with a fa-
vorable prognosis” is recommended. However, the re-
sults of this study suggest that sub-classification-based,
individualized therapeutic strategies should therefore be
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